Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ND0612H continuous subcutaneous levodopa/carbidopa infusion in advanced Parkinson's disease
2015-005078-39Phase 2Completed
- Sponsor
- NeuroDerm Ltd.
- Start
- Mar 2016
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of ND0612, levodopa and carbidopa in Parkinson's disease (PD) (3 arms), sponsored by NeuroDerm Ltd. Primary endpoint: Change from baseline to Day 28 in daily OFF time. Started Mar 2016; status: completed.
02
Drugs
ND0612levodopacarbidopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2015-005078-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005078-39.